Operating Income (Loss) in USD of RIGEL PHARMACEUTICALS INC from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
RIGEL PHARMACEUTICALS INC quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • RIGEL PHARMACEUTICALS INC Operating Income (Loss) for the quarter ending 30 Sep 2025 was $28.4M, a 102% increase year-over-year.
  • RIGEL PHARMACEUTICALS INC Operating Income (Loss) for the twelve months ending 30 Sep 2025 was $119M, a 1152% increase year-over-year.
  • RIGEL PHARMACEUTICALS INC annual Operating Income (Loss) for 2024 was $24.2M.
  • RIGEL PHARMACEUTICALS INC annual Operating Income (Loss) for 2023 was -$20.5M, a 63.1% increase from 2022.
  • RIGEL PHARMACEUTICALS INC annual Operating Income (Loss) for 2022 was -$55.6M, a 345% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

RIGEL PHARMACEUTICALS INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $119M $28.4M +$14.4M +102% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 $105M $61.1M +$60.7M +13570% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025
Q1 2025 $43.9M $12.8M +$19.7M 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025
Q4 2024 $24.2M $16.7M +$14.7M +747% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025
Q3 2024 $9.5M $14.1M +$18.5M 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025
Q2 2024 -$9.02M $447K +$5.71M 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025
Q1 2024 -$14.7M -$6.97M +$5.76M +45.3% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025
Q4 2023 -$20.5M $1.97M -$113K -5.44% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025
Q3 2023 -$20.4M -$4.47M +$13.9M +75.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$34.3M -$5.27M +$7.7M +59.4% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024
Q1 2023 -$42M -$12.7M +$13.5M +51.5% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 -$55.6M $2.08M +$23.5M 01 Oct 2022 31 Dec 2022 10-K 04 Mar 2025
Q3 2022 -$79M -$18.4M +$1.38M +6.99% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023
Q2 2022 -$80.4M -$13M +$83K +0.64% 01 Apr 2022 30 Jun 2022 10-Q 01 Aug 2023
Q1 2022 -$80.5M -$26.3M -$68M -163% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023
Q4 2021 -$12.5M -$21.4M -$2.59M -13.8% 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024
Q3 2021 -$9.91M -$19.8M -$6M -43.6% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$3.9M -$13M +$4.34M +25% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022
Q1 2021 -$8.25M $41.8M +$20.7M +98.6% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022
Q4 2020 -$29M -$18.8M -$1.49M -8.59% 01 Oct 2020 31 Dec 2020 10-K 07 Mar 2023
Q3 2020 -$27.5M -$13.8M -$1.74M -14.5% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021
Q2 2020 -$25.7M -$17.4M +$3.95M +18.5% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021
Q1 2020 -$29.7M $21M +$39.4M 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 -$69.1M -$17.3M -$19.9M -785% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022
Q3 2019 -$49.2M -$12M +$12.3M +50.6% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$61.6M -$21.3M +$4.77M +18.3% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020
Q1 2019 -$66.3M -$18.4M +$6.36M +25.7% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020
Q4 2018 -$72.7M $2.53M +$28.7M 01 Oct 2018 31 Dec 2018 10-K 02 Mar 2021
Q3 2018 -$101M -$24.4M -$6.52M -36.5% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019
Q2 2018 -$94.9M -$26.1M -$6.77M -35% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019
Q1 2018 -$88.1M -$24.7M -$8.53M -52.7% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q4 2017 -$79.6M -$26.2M -$10.4M -66.1% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020
Q3 2017 -$69.2M -$17.9M +$4.88M +21.5% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018
Q2 2017 -$74.1M -$19.3M -$5.7M -41.7% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018
Q1 2017 -$68.4M -$16.2M +$1.37M +7.77% 01 Jan 2017 31 Mar 2017 10-Q 01 May 2018
Q4 2016 -$69.7M -$15.8M -$3.04M -23.8% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019
Q3 2016 -$66.7M -$22.7M -$16M -235% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017
Q2 2016 -$50.7M -$13.6M +$326K +2.33% 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2017
Q1 2016 -$51.1M -$17.6M +$674K +3.7% 01 Jan 2016 31 Mar 2016 10-Q 02 May 2017
Q4 2015 -$51.7M -$12.7M +$9.62M +43% 01 Oct 2015 31 Dec 2015 10-K 06 Mar 2018
Q3 2015 -$61.4M -$6.78M +$14.3M +67.8% 01 Jul 2015 30 Sep 2015 10-Q 01 Nov 2016
Q2 2015 -$75.6M -$14M +$11.5M +45.1% 01 Apr 2015 30 Jun 2015 10-Q 02 Aug 2016
Q1 2015 -$87.1M -$18.2M +$4.14M +18.5% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016
Q4 2014 -$91.2M -$22.4M -$5.42M -32% 01 Oct 2014 31 Dec 2014 10-K 07 Mar 2017
Q3 2014 -$85.8M -$21M +$2.89M +12.1% 01 Jul 2014 30 Sep 2014 10-Q 03 Nov 2015
Q2 2014 -$88.7M -$25.5M -$2.57M -11.2% 01 Apr 2014 30 Jun 2014 10-Q 04 Aug 2015
Q1 2014 -$86.1M -$22.4M +$3.33M +12.9% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015
Q4 2013 -$89.5M -$16.9M +$8.67M +33.9% 01 Oct 2013 31 Dec 2013 10-K 08 Mar 2016
Q3 2013 -$98.1M -$23.9M +$1.64M +6.41% 01 Jul 2013 30 Sep 2013 10-Q 04 Nov 2014
Q2 2013 -$99.8M -$22.9M +$2M +8.03% 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014
Q1 2013 -$102M -$25.7M -$2.4M -10.3% 01 Jan 2013 31 Mar 2013 10-Q 07 May 2014
Q4 2012 -$99.4M -$25.6M +$294K +1.14% 01 Oct 2012 31 Dec 2012 10-K 03 Mar 2015
Q3 2012 -$99.7M -$25.6M -$7.53M -41.7% 01 Jul 2012 30 Sep 2012 10-Q 05 Nov 2013
Q2 2012 -$92.1M -$24.9M -$3.33M -15.4% 01 Apr 2012 30 Jun 2012 10-Q 06 Aug 2013
Q1 2012 -$88.8M -$23.3M -$2.45M -11.7% 01 Jan 2012 31 Mar 2012 10-Q 07 May 2013
Q4 2011 -$86.4M -$25.9M 01 Oct 2011 31 Dec 2011 10-K 04 Mar 2014
Q3 2011 -$18M -$68.4M -136% 01 Jul 2011 30 Sep 2011 10-Q 06 Nov 2012
Q2 2011 -$21.6M -$48.5M -180% 01 Apr 2011 30 Jun 2011 10-Q 07 Aug 2012
Q1 2011 -$20.9M 01 Jan 2011 31 Mar 2011 10-Q 01 May 2012
Q3 2010 $50.4M 01 Jul 2010 30 Sep 2010 10-Q 01 Nov 2011
Q2 2010 $27M 01 Apr 2010 30 Jun 2010 10-Q 02 Aug 2011

RIGEL PHARMACEUTICALS INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $24.2M +$44.7M 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025
2023 -$20.5M +$35.1M +63.1% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025
2022 -$55.6M -$43.1M -345% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2025
2021 -$12.5M +$16.5M +56.9% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024
2020 -$29M +$40.1M +58.1% 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2023
2019 -$69.1M +$3.59M +4.94% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$72.7M +$6.93M +8.71% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021
2017 -$79.6M -$9.88M -14.2% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 -$69.7M -$18M -34.8% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019
2015 -$51.7M +$39.5M +43.3% 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018
2014 -$91.2M -$1.78M -1.99% 01 Jan 2014 31 Dec 2014 10-K 07 Mar 2017
2013 -$89.5M +$9.91M +9.97% 01 Jan 2013 31 Dec 2013 10-K 08 Mar 2016
2012 -$99.4M -$13M -15.1% 01 Jan 2012 31 Dec 2012 10-K 03 Mar 2015
2011 -$86.4M -$122M -345% 01 Jan 2011 31 Dec 2011 10-K 04 Mar 2014
2010 $35.3M 01 Jan 2010 31 Dec 2010 10-K 05 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.